These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW; Lambing CL; Kostenuik PJ; Grauer A Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513 [TBL] [Abstract][Full Text] [Related]
7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis]. Bruhn C Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910 [TBL] [Abstract][Full Text] [Related]
8. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Geusens P Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095 [TBL] [Abstract][Full Text] [Related]
9. Denosumab in osteoporosis and oncology. Burkiewicz JS; Scarpace SL; Bruce SP Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756 [TBL] [Abstract][Full Text] [Related]
10. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Lewiecki EM Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058 [TBL] [Abstract][Full Text] [Related]
11. [Denosumab for treatment of postmenopausal osteoporosis]. Syversen U; Halse JI; Geisler J; Eriksen EF Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295 [TBL] [Abstract][Full Text] [Related]
13. [RANKL inhibition as therapy for joint damage]. Akama H Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581 [TBL] [Abstract][Full Text] [Related]
14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
15. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700 [TBL] [Abstract][Full Text] [Related]
16. The RANKL pathway and denosumab. Dore RK Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901 [TBL] [Abstract][Full Text] [Related]
17. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody]. Wada S; Fukawa T; Kamiya S Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149 [No Abstract] [Full Text] [Related]
18. [Anti-RANKL antibody for the treatment of rheumatoid arthritis]. Tanaka Y Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029 [TBL] [Abstract][Full Text] [Related]